The company has entered into a collaboration agreement with DiaUnion, a center of excellence in type 1 diabetes, to identify participants for the DiaPrecise trial.

DiaPrecise is an open-label trial evaluating the safety, feasibility and immune response of intralymphatic injections of Diamyd in children at risk of developing type 1 diabetes who also carry the HLA DR3-DQ2 genotype. The DiaPrecise trial has been initiated and is ongoing at the Department of Clinical Sciences at Lund University, Malmö.

“We are thrilled to partner with DiaUnion around the precision medicine trial DiaPrecise,” says Ulf Hannelius, President & CEO of Diamyd Medical. “An infrastucture for screening of type 1 diabetes is a prerequisite to evaluate preventive treatments, and this partnership is important to advance our goal of delaying or preventing the progression of type 1 diabetes with the antigen-specific immunotherapy Diamyd.”

DiaPrecise

DiaPrecise is the first precision prevention trial with Diamyd, and is conducted under the ASSET program (AI for the Sustainable Prevention of Autoimmunity in Society) funded by the Swedish Innovation Agency VINNOVA. DiaUnion is a consortium coordinated by the Medicon Valley Alliance involving also the Steno Diabetes Center Copenhagen and Lund University, Malmö, establishing a screening program to identify individuals positive for diabetes autoantibodies, and there at high risk for the disease.

“DiaUnion’s long term goal is to prevent type 1 diabetes,” says Finn Kristensen, Program Director, DiaUnion. “Screening programs currently constitute a bottleneck for the identification of persons at risk and thus for the development of new therapies. We are excited to enter into our first industry partnership with Diamyd Medical as a step towards this goal.”

Photo of Ulf Hannelius: Diamyd Medical